The newly identified action of miR-505 in augmenting the level of proinflammatory mediators such as TNF-α in PBMCs (Figure 4A) corroborates vascular inflammation (Figure 2C) and kidney inflammation (Figure 3) as a result of agomir-505 in vivo administration. The gene discussed is TNF; the disease is nephritis.